Prospective and retrospective studies showed that certain adverse events, including hypertension, HSF, asthenia and/or fatigue, neutropenia and thrombocytopenia, may be predictive of clinical outcome in patients with mRCC treated with inhibitors of the VEGF pathway (Davis et al., 2011; Di Fiore, Rigal, Menager, Michel, & Pfister, 2011; Donskov et al., 2011; Donskov et al., 2015; Michaelson et al., 2011; Poprach et al., 2012; Rini et al., 2011; Rini et al., 2015; Soerensen et al., 2016; Yada et al., 2014). This evidence concerns the gene VEGFA and neutropenia.